Befotertinib vs Icotinib as First-Line Therapy for Patients With EGFR-Mutated Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
Lancet Respir Med 2023 May 24;[EPub Ahead of Print], S Lu, J Zhou, H Jian, L Wu, Y Cheng, Y Fan, J Fang, G Chen, Z Zhang, D Lv, L Jiang, R Wu, X Jin, X Zhang, J Zhang, C Xie, G Sun, D Huang, J Cui, R Guo, Z Han, Z Chen, J Liang, W Zhuang, X Hu, A Zang, Y Zhang, S Cang, Y Lan, X Chen, L Liu, X Li, J Chen, R Ma, Y Guo, P Sun, P Tian, Y Pan, Z Liu, P Cao, L Ding, Y Wang, X Yuan, P WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.